Alessia Bottos

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances

Published: January 16, 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances

Published: January 16, 2026

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 20, 2025

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Journal: Blood advances

Published: April 21, 2025

Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Journal: Blood advances

Published: April 21, 2025

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Journal: Blood

Published: February 20, 2025

gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles.

gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles.

Journal: Leukemia & lymphoma

Published: January 10, 2025

NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.

NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.

Journal: Leukemia & lymphoma

Published: February 10, 2024

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 14, 2023

Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma.

Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma.

Journal: Cancer discovery

Published: September 07, 2022

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.

Journal: Leukemia & lymphoma

Published: January 20, 2022

Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.

Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 04, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026